Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week Searches For Meaning In Deal Break-Ups

Executive Summary

Amid a dearth of private-sector deals, we review some of this year’s break-ups, take a closer look at the Leukemia & Lymphoma Society’s deal-making strategy and highlight two deals from the U.K.’s Cancer Research Technology, as well as a licensing pact between Adimab and Alector.

Advertisement

Related Content

After CEO’s Abrupt Resignation, Teva Management Emphasizes Stability
Deals Of The Week: Tellingly, Teva And Lonza Part Ways
Lackluster Fostamatinib Results Prompt AstraZeneca To Drop Rigel Deal
New $80 Million U.K. Asset-Centric Cancer Research Fund Set Up With EU, Charity Funding
With Capital Scarce, Charities Emerge As A Stronger Force On Start-Up Scene
Venture Philanthropy: The New Venture Capital?

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS055717

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel